Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Triptans and ischemia

This article was originally published in The Tan Sheet

Executive Summary

Triptan overuse does not increase the risk for ischemic attacks, but overuse of ergotamine may increase this risk, particularly in patients taking cardiovascular drugs simultaneously, according to the results of a retrospective case-controlled study published in the Oct. 10 issue of Neurology. E. Wammes-van der Heijden, et al., Utrecht University, The Netherlands, identified 188 cases of hospitalization related to ischemia and 689 controls were assigned the same index date as the cases. Researchers defined overuse of migraine medications triptans or ergotamine as 90 or more defined daily doses during a year. Triptan overuse was not associated with increased risk for ischemic complication (odds ratio of 0.96), but ergotamine overuse was related to higher risk of ischemia (odds ratio of 2.55). GlaxoSmithKline received nonprescription approval for Imigran Recovery (sumatriptan 50 mg) from the UK's Medicines & Healthcare products Regulatory Agency in May, which may open the possibility for a future U.S. triptan switch (1"The Tan Sheet" May 22, 2006, p. 3). Additionally, a generic Imitrex is slated for launch in 2008 (2"The Tan Sheet" Oct. 16, 2006, In Brief)...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS099905

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel